Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
European Institute of Oncology
R-Pharm
OncoResponse, Inc.
Massachusetts General Hospital
Kineta Inc.
University Health Network, Toronto
Jules Bordet Institute
Revolution Medicines, Inc.
Imperial College London
Shanghai Fengxian District Central Hospital
Beijing Immunochina Medical Science & Technology Co., Ltd.
CureVac
SpeciCare
Fundacion Clinic per a la Recerca Biomédica
Mie University
Threshold Pharmaceuticals
Institut National de la Santé Et de la Recherche Médicale, France